Open AccessWho Can Receive the Benefit of a Palbociclib Add-On in Patients With HR+HER2– Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy?
Author(s) -
Yukino Kawamura,
Akihiko Shimomura,
Chikako Shimizu
Publication year - 2021
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.21.01174
Subject(s) - medicine , palbociclib , oncology , chemotherapy , breast cancer , disease , cancer , neoadjuvant therapy , trastuzumab , gynecology , metastatic breast cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom